Essential Updates in the Surgical Management of Inflammatory Bowel Disease: Current Topics From 2024 to Mid-2026.

IF 3.2 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY
Yoshiki Okita, Tadanobu Shimura, Mikio Kawamura, Yuhki Koike, Yuji Toiyama
{"title":"Essential Updates in the Surgical Management of Inflammatory Bowel Disease: Current Topics From 2024 to Mid-2026.","authors":"Yoshiki Okita, Tadanobu Shimura, Mikio Kawamura, Yuhki Koike, Yuji Toiyama","doi":"10.1002/ags3.70271","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory bowel disease management has undergone a major transformation with the introduction of treat-to-target strategies and highly effective biologic and small-molecule therapies. Although these advances have reduced the overall requirement for surgery, operative intervention remains essential for selected patients with ulcerative colitis (UC) and Crohn's disease (CD). Additionally, the role of surgery has evolved considerably, driven by changes in the disease phenotype, advances in minimally invasive techniques, and growing interest in disease-modifying surgical strategies. In UC, colectomy rates have declined, while surgical indications have increasingly shifted toward acute severe colitis, dysplasia, and colorectal cancer. Minimally invasive approaches, including robotic-assisted and transanal techniques, have expanded rapidly and are associated with improved perioperative and functional outcomes. In CD, overall surgical rates have decreased; however, surgery remains indispensable for fibrostenotic, penetrating, and perianal disease. Recent developments include increasing evidence supporting Kono-S anastomosis for reducing postoperative recurrence and ongoing investigation of mesentery-based surgical strategies. Robotic-assisted ileocolic resection has emerged as a safe and feasible minimally invasive option in selected patients. The prevention of postoperative recurrence has evolved toward risk-stratified prophylaxis, early biologic therapy, and treat-to-target monitoring. In perianal CD, multidisciplinary management combining medical and surgical treatment remains the cornerstone of care, while newer biologics and small-molecule therapies continue to expand therapeutic options. This review summarizes the major advances in the surgical management of UC and CD reported between January 2024 and June 2026 and highlights the evolving role of surgery in contemporary multidisciplinary care of inflammatory bowel disease.</p>","PeriodicalId":8030,"journal":{"name":"Annals of Gastroenterological Surgery","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13580014/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Gastroenterological Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ags3.70271","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Inflammatory bowel disease management has undergone a major transformation with the introduction of treat-to-target strategies and highly effective biologic and small-molecule therapies. Although these advances have reduced the overall requirement for surgery, operative intervention remains essential for selected patients with ulcerative colitis (UC) and Crohn's disease (CD). Additionally, the role of surgery has evolved considerably, driven by changes in the disease phenotype, advances in minimally invasive techniques, and growing interest in disease-modifying surgical strategies. In UC, colectomy rates have declined, while surgical indications have increasingly shifted toward acute severe colitis, dysplasia, and colorectal cancer. Minimally invasive approaches, including robotic-assisted and transanal techniques, have expanded rapidly and are associated with improved perioperative and functional outcomes. In CD, overall surgical rates have decreased; however, surgery remains indispensable for fibrostenotic, penetrating, and perianal disease. Recent developments include increasing evidence supporting Kono-S anastomosis for reducing postoperative recurrence and ongoing investigation of mesentery-based surgical strategies. Robotic-assisted ileocolic resection has emerged as a safe and feasible minimally invasive option in selected patients. The prevention of postoperative recurrence has evolved toward risk-stratified prophylaxis, early biologic therapy, and treat-to-target monitoring. In perianal CD, multidisciplinary management combining medical and surgical treatment remains the cornerstone of care, while newer biologics and small-molecule therapies continue to expand therapeutic options. This review summarizes the major advances in the surgical management of UC and CD reported between January 2024 and June 2026 and highlights the evolving role of surgery in contemporary multidisciplinary care of inflammatory bowel disease.

炎症性肠病外科治疗的基本更新:从2024年到2026年中期的当前主题。
随着靶向治疗策略和高效的生物和小分子疗法的引入,炎症性肠病的治疗经历了重大转变。尽管这些进步降低了手术的总体需求,但对于溃疡性结肠炎(UC)和克罗恩病(CD)患者,手术干预仍然是必要的。此外,由于疾病表型的变化、微创技术的进步以及对疾病修饰手术策略的兴趣日益增加,手术的作用已经发生了很大的变化。在UC中,结肠切除术率已经下降,而手术指征越来越多地转向急性严重结肠炎、发育不良和结直肠癌。微创入路,包括机器人辅助和经肛门技术,已经迅速扩展,并与改善围手术期和功能预后相关。在乳糜泻中,总体手术率有所下降;然而,对于纤维狭窄、穿透性和肛周疾病,手术仍然是必不可少的。最近的进展包括越来越多的证据支持Kono-S吻合术减少术后复发和基于肠系膜的手术策略的持续研究。机器人辅助回肠结肠切除术已成为一种安全可行的微创选择。术后复发的预防已经向风险分层预防、早期生物治疗和治疗目标监测发展。在肛周CD中,医学和外科治疗相结合的多学科管理仍然是护理的基石,而新的生物制剂和小分子疗法继续扩大治疗选择。本综述总结了2024年1月至2026年6月期间UC和CD手术治疗的主要进展,并强调了手术在当代炎症性肠病多学科治疗中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Gastroenterological Surgery
Annals of Gastroenterological Surgery GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
5.30
自引率
11.10%
发文量
98
审稿时长
11 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书